Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 1/20 | 0.61 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | ABCC2 | Q92887 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12369352 | 1.00 | CTSS (0.61) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL8004083 | 1.00 | CTSS (0.61) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL10284054 | 0.93 | CTSS (0.65) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL12356965 | 0.93 | CTSS (0.65) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL15216116 | 0.92 | CTSS (0.58) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL10283472 | 0.92 | CTSS (0.73) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL3669873 | 0.88 | CTSS (0.55) | CTSSCTSBADRB3ADRA2BADRA2C | |
| Hydrochloric Acid SCHEMBL3669878 | 0.88 | CTSS (0.55) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL10283892 | 0.88 | CTSS (0.50) | CTSSCTSBADRB3ADRA2BADRA2C | |
| SCHEMBL3670721 | 0.88 | CTSS (0.56) | CTSSCTSBADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250174-B1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS INC (US) | 2013-08-28 | — | — | EP | disclosed |
| US-8003659-B2 | Macrocyclic serine protease inhibitors | INDENIX PHARMACEUTICALS, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | IDENIX PHARMACEUTICALS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202480-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS | SERPINB1, SPINT2, PRSS1 | CTSS 43/4885CTSB 55/4885ADRB3 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.